Elan Gains Most in 3 Months After Tysabri Comments - Bloomberg
Links shared publicly online about this topic.
- 382total visits
Elan Gains Most in 3 Months After Tysabri Comments - Bloomberg
Elan Corp. rose the most in three months after a Berenberg Bank analyst said the share price doesn--™t recognize the value of Tysabri and the potential for the Irish drugmaker--™s Alzheimer--™s treatment, bapineuzumab.
View full resource at bloomberg.com
Tags: Multiple Sclerosis Medication, Drug, Tysabri, Biogen Idec
Most Recently Shared on April 7, 2011 at 1:59 pm By:
Test to assess risk of deadly side effect boosts Tysabri, MS drug Biogen Idec makes in RTP. (Bloomberg) http://bloom.bg/hpHBn9 #SITT
Advertisement
